4-chloro-m-cresol test - A possible supplementary test for diagnosis of malignant hyperthermia susceptibility

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 8, 1997, Pages 967-972

  Ording H ^a   Glahn, K ^b   Gardi, T ^b   Fagerlund, T ^b   Bendixen, D ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

4 chloro m cresol test; Anesthesia complications; Caffeine; Calcium channel; Diagnosis; Halothane; in vitro contracture test; Inhalational anesthesia; Malignant hyperthermia; Ryanodine receptor

Indexed keywords

CAFFEINE; CHLOROCRESOL; HALOTHANE; RYANODINE;

ANESTHESIA COMPLICATION; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; INHALATION ANESTHESIA; MALIGNANT HYPERTHERMIA; MUSCLE TWITCH; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0030762205     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04821.x     Document Type: Article

References (19)

1. European MH Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984: 56: 1267-1269.
2. European MH Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985: 57: 1038.
3. Ørding H. Investigation of malignant hyperthermia in Denmark. Dan Med Bull 1996: 43: 111-125.
4. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991: 11: 751-755.
5. Gillard EF, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK et al. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992: 13: 1247-1254.
6. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993: 5: 51-55.
7. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993: 5: 46-50.
8. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA et al. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implication for diagnosis and heterogeneity studies. Hum Mol Genet 1994: 3: 471-476.
9. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K et al. Detection of a novel Ryr1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet 1994: 3: 1855-1858.
10. Quane KA, Keating KE, Healy JMS, Manning BM, Krivosic-Horber R, Krivosic I et al. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994: 23: 236-239.
11. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991: 66: 611-613.
12. Lenzen C, Roewer N, Wappler F, Scholz J, Kahl J, Blank M et al. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br J Anaesth 1993: 71: 242-246.
13. Herrmann-Frank A, Richter M, Sarközi S, Mohr U, Lehmann-Horn F. 4-Chloro-m- cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta 1996: 1289: 31-40.
14. Galloway GJ, Denborough MA. Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 1986: 58: 447-450.
15. Larach MG, Landis JR, Shirk SJ, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in man: improving sensitivity of the caffeine halothane contracture test. Anesthesiology 1992: 77: A1052.
16. SigmaStat version 2.0 for Windows 95, Jandel Scientific Software 1995. Erkrath, Germany: Jandel Corporation.
17. Islander G, Bendixen D, Ranklev-Twetman E, Ørding H. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands. Acta Anaesthesiol Scand 1996: 40: 579-584.
18. Pessah IN, Lynch III C, Gronert GA. Complex pharmacology of malignant hyperthermia. Anesthesiology 1996: 84: 1275-1279.
19. 2+ channel. Anesthesiology 1996: 84: 1380-1385.